Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**1-Phenylcyclohexylamine** is a synthetic aralkylamine compound with the molecular formula C12H17N and a molecular weight of approximately 175.27 g/mol[2][6]. It is structurally related to phencyclidine (PCP), differing by the replacement of PCP’s piperidine ring with a primary amino group[5]. This compound acts as an analog and precursor in the synthesis of PCP[4]. Pharmacologically, it has been shown to possess anticonvulsant activity in animal models, particularly effective in blocking maximal electroshock seizures and antagonizing NMDA-induced behavioral effects at higher doses[5]. Its mechanism involves noncompetitive antagonism at ionotropic glutamate receptors (notably NMDA receptor-coupled channels)[5]. It is classified as an experimental and illicit substance, not approved for medical use, and is listed as a DEA Schedule II controlled substance due to its high potential for abuse and dependence[2][1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1-phenylcyclohexylamine.